Interview with Dr. John Marshall and Dr. Tony Shields on MI FOLFOXaiTM
b'Caris Precision Oncology Alliance\\u2122 Chairman, Dr. Chadi Nabhan, sits down with Dr. John Marshall, Chief, Division of Hematology/Oncology at Georgetown University, and Dr. Tony Shields, Associate Center Director, Clinical Sciences at Karmanos Cancer Center Institute. Both are co-authors on the December 8, 2020 paper: Clinical validation of a machine-learning derived signature predictive of outcomes from first-line oxaliplatin-based chemotherapy in advanced colorectal cancer found in Clinical Cancer Research, a journal of the American Association for Cancer Research.\\n\\nIn this interview Dr. Marshall and Dr. Shields discuss the findings of their paper and how we can better predict which metastatic colorectal cancer patients will benefit from first-line FOLFOX+BV followed by FOLFIRI+BV or vice versa.\\n\\nFor more information, please visit: www.CarisLifeSciences.com/MI-FOLFOXai/'